Here, we present the results of RNA sequencing studies from an exploratory analysis in which HER2-positive early-stage breast cancer patients received tissue biopsies prior to and after receiving a single dose of neoadjuvant HER2-directed therapy with trastuzumab. The gene discussed is ERBB2; the disease is breast cancer.